Canopy Growth Corporation and Canopy USA, LLC Announce Filing of Early Warning Report regarding TerrAscend Corp.

Canopy Growth Corporation (" Canopy " or the " Company ") (TSX: WEED) (NASDAQ: CGC) and Canopy USA LLC (" Canopy USA ") today announced that each of the Company and Canopy USA has filed an early warning report under National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the Company's direct and indirect disposition of, and Canopy USA's direct and indirect acquisition of beneficial ownership of: (i) 38,890,570 exchangeable shares (the " Exchangeable Shares ") in the capital of TerrAscend Corp. (" TerrAscend "); (ii) an option to acquire 1,072,450 common shares (the " Common Shares ") in the capital of TerrAscend for an aggregate exercise price of $1.00 (the " TerrAscend Option "); (ii) 2,152,733 Common Share purchase warrants (the " Warrants ") with an exercise price of C$3.74 per Common Share (the " TerrAscend 1A Warrants "); (iv) 15,656,242 Warrants with an exercise price of C$5.14 per Common Share (the " TerrAscend 1B Warrants "); (v) 2,225,714 Warrants with an exercise price of C$5.95 per Common Share (the " TerrAscend 2A Warrants "); (vi) 333,723 Warrants with an exercise price of C$6.49 per Common Share (the " TerrAscend 2B Warrants "); (vii) 1,926,983 Warrants with an exercise price of C$15.28 per Common Share (the " TerrAscend 3A Warrants "); and 178,735 Warrants with an exercise price of C$17.19 per Common Share (the " TerrAscend 3B Warrants ", together with the TerrAscend 1A Warrants, TerrAscend 1B Warrants, the TerrAscend 2A Warrants, TerrAscend 2B Warrants and TerrAscend 3A Warrants, the " TerrAscend Warrants ").

Canopy Growth Corporation and Canopy USA, LLC Announce Filing of Early Warning Report regarding TerrAscend Corp. (CNW Group/Canopy Growth Corporation)

On October 24, 2022 , Canopy Growth, certain of its wholly-owned subsidiaries and Canopy USA completed a series of transactions to effect a reorganization (the " Reorganization "). Pursuant to the Reorganization, among other things, Canopy USA or entities controlled by Canopy USA , acquired 38,890,570 Exchangeable Shares, the TerrAscend Option to acquire 1,072,450 Common Shares and 22,474,130 TerrAscend Warrants directly and indirectly from Canopy Growth.

Completion of the Reorganization resulted in a 100% decrease in Canopy Growth's interest in the Exchangeable Shares on a non-diluted basis and an approximate 19.9% decrease in Canopy Growth's interest in the Common Shares on a partially diluted basis, assuming the conversion of the 38,890,570 Exchangeable Shares into Common Shares and the exercise of the 22,474,130 TerrAscend Warrants and the TerrAscend Option to acquire 1,072,450 Common Shares. Immediately prior to the completion of the Reorganization, Canopy Growth owned 38,890,570 Exchangeable Shares and 22,474,130 TerrAscend Warrants and was deemed to own 1,072,450 Common Shares that are subject to the TerrAscend Option, representing 100% of the issued and outstanding Exchangeable Shares on a non-diluted basis and approximately 19.9% of the issued and outstanding Common Shares on a partially-diluted basis, assuming the conversion of the 38,890,570 Exchangeable Shares into Common Shares and the exercise of the 22,474,130 TerrAscend Warrants and the TerrAscend Option to acquire 1,072,450 Common Shares.

Immediately following the Reorganization, Canopy Growth no longer beneficially owns or controls any securities in the capital of TerrAscend. While Canopy Growth currently has no immediate plans or intentions with respect to the securities of TerrAscend, depending on market conditions, general economic and industry conditions, trading prices, TerrAscend's business, financial condition and prospects and/or other relevant factors, Canopy Growth may develop such plans or intentions in the future and, at such time, may from time to time acquire additional securities of TerrAscend.

Immediately prior to completion of the Reorganization, neither Canopy USA nor Canopy USA I Limited Partnership, Canopy USA II Limited Partnership or Canopy USA III Limited Partnership (collectively, the " Canopy USA LPs "), of which Canopy USA is the general partner, beneficially owned or exercised control or direction over any Common Shares or convertible securities of TerrAscend.

Immediately following the Reorganization, Canopy USA beneficially owns, and exercises control or direction over, 38,890,570 Exchangeable Shares and 22,474,130 TerrAscend Warrants and is deemed to own 1,072,450 Common Shares that are subject to the TerrAscend Option, representing 100% of the issued and outstanding Exchangeable Shares on a non-diluted basis and approximately 19.9% of the issued and outstanding Common Shares on a partially-diluted basis, assuming the conversion of 38,890,570 Exchangeable Shares into Common Shares and the exercise of the 22,474,130 TerrAscend Warrants and the TerrAscend Option to acquire 1,072,450 Common Shares.

Canopy USA's beneficial ownership interest is by virtue of its control of the Canopy USA LPs. Canopy USA LP I beneficially owns, and exercises control or direction over, 2,105,718 TerrAscend Warrants, representing approximately 0.8% of the issued and outstanding Common Shares on a partially-diluted basis, assuming the conversion of 2,105,718 TerrAscend Warrants. Canopy USA LP II beneficially owns, and exercises control or direction over, 38,890,570 Exchangeable Shares and is deemed to own 1,072,450 Common Shares that are subject to the TerrAscend Option, representing approximately 13.7% of the issued and outstanding Common Shares on a partially-diluted basis, assuming the conversion of 38,890,570 Exchangeable Shares into Common Shares and the exercise of the TerrAscend Option. Canopy USA LP III beneficially owns, and exercises control or direction over, 20,368,412 TerrAscend Warrants, representing approximately 7.5% of the issued and outstanding Common Shares on a partially-diluted basis, assuming the conversion of 20,368,412 TerrAscend Warrants.

Canopy USA beneficially holds the TerrAscend securities for investment purposes. While Canopy USA and/or the Canopy USA LPs currently have no immediate plans or intentions with respect to the securities of TerrAscend, depending on market conditions, general economic and industry conditions, trading prices, TerrAscend's business, financial condition and prospects and/or other relevant factors, Canopy USA and/or the Canopy USA LPs may develop such plans or intentions in the future and, at such time, may from time to time acquire additional securities, dispose of some or all of the existing or additional securities or may continue to hold the securities of TerrAscend.

A copy of the early warning report filed by Canopy Growth with respect to the securities of TerrAscend will be available under TerrAscend's profile on SEDAR at www.sedar.com or by contacting Canopy Growth at 855 558-9333.

A copy of the early warning report filed by Canopy USA will be available under TerrAscend's profile on SEDAR at www.sedar.com or by contacting Canopy USA at (415) 882-0117.

TerrAscend's head office is located at P.O. Box 43125, Mississauga, Ontario L5B 4A7. Canopy Growth's head office is located at 1 Hershey Drive, Smiths Falls, Ontario , K7A 0A8 and Canopy USA's head office is located at 35715 Hwy 40, Ste D102, Evergreen, Colorado , 80439.

About Canopy Growth

Canopy Growth (TSX:WEED, NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, Canopy Growth offers product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Canopy Growth's global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany . Through Canopy Growth's award-winning Tweed banner, Canopy Growth reaches its adult-use consumers and has built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada , the U.S., and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional hemp derived CBD products to the U.S. through its First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands.

Notice Regarding Forward-Looking Information

This news release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, Canopy USA or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements regarding with respect to Canopy Growth's, Canopy USA and/or Canopy USA LP's expectations in connection with the sale or purchase of additional securities of TerrAscend in the future, on the open market or in private transactions and expectations for other economic, business, and/or competitive factors. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets and the impacts of increased rates of inflation; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis, political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of Canopy Growth filed with Canadian securities regulators and available under the Canopy Growth's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission through EDGAR at www.sec.gov/edgar , including Canopy Growth's annual report on Form 10-K for the year ended March 31, 2022 .

In respect of the forward-looking statements and information, Canopy Growth and Canopy USA have provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although Canopy Growth and Canopy USA believe that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Growth and Canopy USA have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and neither Canopy Growth nor Canopy USA undertake any obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/canopy-growth-corporation-and-canopy-usa-llc-announce-filing-of-early-warning-report-regarding-terrascend-corp-301659116.html

SOURCE Canopy Growth Corporation

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/October2022/25/c0680.html

News Provided by Canada Newswire via QuoteMedia

WEED:CA,CGC
The Conversation (0)
Resource Investing

Big News Roundup Resource Investing

Feb 28 Big News: QMX Intersects 38.7 g/t Gold Over 3.5 Metres and 34.9 g/t Gold Over 3.0 Metres, Renforth Drills 1.25 g/t Au over 7.5m at a Vertical Depth of 330m, IsoEnergy Intersects 8.5m of 33.9 Percent U3O8, Including 5.0m of 57.1 Percent U3O8 at the Hurricane Zone

News of the coronavirus continuing to spread in several jurisdictions around the world has caused stock markets to tumble this week, including the Dow Jones, which had its worst week since the financial crisis in 2008. The TSX Composite dropped 2.8 percent to open Friday at 16,258.29 while the TSV Venture Exchange lost 19.37 points to open Friday’s session down 3.7 percent at 501.22. Despite the market reaction, experts remain adamant that the general public need not worry about the virus. “I don’t think we’re at the level yet where the average person needs to be panicking about this,” Dr. Brian Garibaldi, medical director of Johns Hopkins Hospital’s biocontainment unit, told Yahoo Finance’s The Final Round. “But I think it’s important to remember that we’re still in the middle of this flu season. And those basic efforts can do a lot to prevent the spread of this virus.”

Keep reading...Show less

Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.

To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations . To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company's website.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Lake Placid, Florida

New Highlands County location will host grand opening celebration Friday, November 1 st

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Lake Placid, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Florida Medical Cannabis Dispensaries in Bonita Springs and St. Augustine

Grand opening celebrations scheduled for Friday, October 18 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of new Florida medical cannabis dispensaries in Bonita Springs and St. Augustine .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. to Hold Third Quarter 2024 Results Conference Call on November 5, 2024

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Tuesday, November 5, 2024 at 8:30 AM Eastern Time following the release of its third quarter 2024 financial results.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.

North American toll free: 1-844-824-3830


Passcode:


3735709


International: 1-412-542-4136


Passcode:


3735709


A live audio webcast of the conference call will be available at:
Trulieve Third Quarter 2024 Results Call

An archived replay of the webcast will be available at:
https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve_
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-third-quarter-2024-results-conference-call-on-november-5-2024-302274503.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2024/14/c7404.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.

Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will reach AU$3.73 billion in 2024 and grow at an annual rate of 3.22 percent, culminating in market volume worth AU$4.53 billion by 2029.

However, Australia’s cannabis industry is still young. Despite there being a strong case for a regulated market, which was outlined in a July 2024 report by the Penington Institute, recreational use is not legal and medical access remains limited and regulated. Yet, public support for legalisation is growing. YouGov data released in January 2024 showed that over half of Australians polled are in favour of decriminalising cannabis, and half of the respondents between the ages of 18 and 49 support legalising personal use.

In 2023, the Australian Greens, the country’s only seat-holding federal party in favour of legalisation, introduced the Legalising Cannabis Bill 2023, sponsored by the party’s leader Senator David Shoebridge. This was Australia’s first parliamentary effort to legalise cannabis.

Keep reading...Show less

Spinach® Is the Number One Cannabis Brand in Canada

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, is proud to announce that its award-winning brand Spinach® has risen to the best-selling cannabis brand in the Canadian market. 1 Spinach's market share outperformance represents Cronos' relentless commitment to quality, innovation, and bringing differentiated products to the competitive Canadian adult-use market.

Since launching in November 2018, Spinach has quickly become the preferred choice among new and seasoned adult consumers alike. The success of Spinach is bolstered by its best-selling and breakthrough portfolio of products, including ranking first in both edibles and flower. 1

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×